New! Sign up for our free email newsletter.
Science News
from research organizations

Skin patch shows promise for toddlers with peanut allergy

Lurie Children's clinical trials program for food allergies contributed to global study

Date:
May 23, 2023
Source:
Ann & Robert H. Lurie Children's Hospital of Chicago
Summary:
A global phase 3 clinical trial found that a year-long immunotherapy through a skin patch safely desensitized toddlers with peanut allergy, lowering the risk of a severe allergic reaction from accidental exposure.
Share:
FULL STORY

A global phase 3 clinical trial that included Ann & Robert H. Lurie Children's Hospital of Chicago found that a year-long immunotherapy through a skin patch safely desensitized toddlers with peanut allergy, lowering the risk of a severe allergic reaction from accidental exposure. Results of this randomized, double-blind, placebo-controlled trial for children 1-3 years of age, funded by DBV Technologies, were published in the New England Journal of Medicine.

"We were excited to contribute to this landmark study that carries so much promise for our young patients with peanut allergy," said co-author Melanie Makhija, MD, who was the Principal Investigator of the study at Lurie Children's and is an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. "Children who originally reacted to a small fraction of a peanut were able to tolerate the equivalent of one to four peanuts after completing the treatment course. This means that these children will be well protected from accidental exposure to peanuts. Importantly, we found that the peanut patch was safe, with very low chances of a severe allergic reaction. This is terrific news for families of kids with peanut allergies."

Peanut allergy affects approximately 2 percent of children in the United States, Canada and other westernized countries, and it commonly persists into adulthood. Life-threatening allergic reactions can be triggered by unintentional exposure to minute quantities, including through products manufactured on shared equipment as peanuts. Currently, there are no approved treatments for peanut-allergic children younger than 4 years of age.

Since 2012, the clinical trials program for food allergies at Lurie Children's has enrolled patients on numerous studies of novel treatments, including the oral immunotherapy for peanuts that has been approved by the Food and Drug Administration (FDA). Ongoing trials are available for all age groups, from infancy to young adulthood. The program is led by Principal Investigators Elizabeth Lippner, MD, and Abigail Lang, MD, MSCI.

Research at Ann & Robert H. Lurie Children's Hospital of Chicago is conducted through Stanley Manne Children's Research Institute. The Manne Research Institute is focused on improving child health, transforming pediatric medicine and ensuring healthier futures through the relentless pursuit of knowledge. Lurie Children's is a nonprofit organization committed to providing access to exceptional care for every child. It is ranked as one of the nation's top children's hospitals by U.S. News & World Report. Lurie Children's is the pediatric training ground for Northwestern University Feinberg School of Medicine.


Story Source:

Materials provided by Ann & Robert H. Lurie Children's Hospital of Chicago. Note: Content may be edited for style and length.


Journal Reference:

  1. Matthew Greenhawt, Sayantani B. Sindher, Julie Wang, Michael O’Sullivan, George du Toit, Edwin H. Kim, Deborah Albright, Sara Anvari, Nicolette Arends, Peter D. Arkwright, Philippe Bégin, Katharina Blumchen, Thierry Bourrier, Terri Brown-Whitehorn, Heather Cassell, Edmond S. Chan, Christina E. Ciaccio, Antoine Deschildre, Amandine Divaret-Chauveau, Stacy L. Dorris, Morna J. Dorsey, Thomas Eiwegger, Michel Erlewyn-Lajeunesse, David M. Fleischer, Lara S. Ford, Maria Garcia-Lloret, Lisa Giovannini-Chami, Jonathan O. Hourihane, Nicola Jay, Stacie M. Jones, Leigh Ann Kerns, Kirsten M. Kloepfer, Stephanie Leonard, Guillaume Lezmi, Jay A. Lieberman, Jeanne Lomas, Melanie Makhija, Christopher Parrish, Jane Peake, Kirsten P. Perrett, Daniel Petroni, Wolfgang Pfützner, Jacqueline A. Pongracic, Patrick Quinn, Rachel G. Robison, Georgiana Sanders, Lynda Schneider, Hemant P. Sharma, Juan Trujillo, Paul J. Turner, Katherine Tuttle, Julia E. Upton, Pooja Varshney, Brian P. Vickery, Christian Vogelberg, Brynn Wainstein, Robert A. Wood, Katharine J. Bee, Dianne E. Campbell, Todd D. Green, Rihab Rouissi, Aurélie Peillon, Henry T. Bahnson, Timothée Bois, Hugh A. Sampson, A. Wesley Burks. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. New England Journal of Medicine, 2023; 388 (19): 1755 DOI: 10.1056/NEJMoa2212895

Cite This Page:

Ann & Robert H. Lurie Children's Hospital of Chicago. "Skin patch shows promise for toddlers with peanut allergy." ScienceDaily. ScienceDaily, 23 May 2023. <www.sciencedaily.com/releases/2023/05/230523123752.htm>.
Ann & Robert H. Lurie Children's Hospital of Chicago. (2023, May 23). Skin patch shows promise for toddlers with peanut allergy. ScienceDaily. Retrieved April 24, 2024 from www.sciencedaily.com/releases/2023/05/230523123752.htm
Ann & Robert H. Lurie Children's Hospital of Chicago. "Skin patch shows promise for toddlers with peanut allergy." ScienceDaily. www.sciencedaily.com/releases/2023/05/230523123752.htm (accessed April 24, 2024).

Explore More

from ScienceDaily

RELATED STORIES